Cardiomyopathy

A recent study from Duke University spotlighted papSCAR’s substantial association with both cardiovascular mortality and arrhythmia.

The Q3 recap for cardiology spotlights major FDA decisions, new heart failure and hypertension guidelines, and top trial results and research.

Read about groundbreaking FDA decisions, exciting new heart failure research, and more.

Aficamten shows superior exercise capacity improvements over metoprolol for patients with oHCM.

New 96-week data reveals aficamten's significant benefits for patients with nonobstructive hypertrophic cardiomyopathy.

Acoramidis significantly lowers cardiovascular event risk in ATTR-CM, emphasizing the need for early diagnosis & treatment.

A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.

Aficamten displayed superior improvements in peak oxygen uptake and hemodynamics compared to the most commonly used beta-blocker for symptomatically obstructive HCM.

Capricor Therapeutics intends to resubmit a BLA for the potential first-in-class treatment with topline data from the ongoing HOPE-3 trial in Q3 2025.

Discover key advancements and setbacks in cardiovascular medicine from May 2025, shaping the future of cardiometabolic care and treatment options.

Latest analysis of the HELIOS-B trial finds vutrisiran significantly lowers mortality and cardiovascular events in patients with ATTR-CM.

Hosts explore the latest advancements in amyloidosis treatment, with expert insights on emerging therapies and patient care strategies.

The model could allow cardiologists to inform and prepare patients before symptoms of hypertrophic cardiomyopathy make themselves known.

Bhatt discusses his expectations for the future of cardiology in 2025, including GLP-1-RAs and the push towards combination therapy.

Ruff discusses his expectations for cardiology for the rest of 2025, including new research into GLP-1 receptor agonists.

Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.

Our Q1 2025 recap for cardiology spotlights 6 regulatory updates, 5 key trial announcements, and top expert perspectives in cardiac care.

Ahmad Masri, MD, MS, discusses how new options change the historic approach to the treatment of newly diagnosed ATTR-CM.

Daniel Judge, MD, discusses data from a prespecified analysis of ATTRibute-CM examining the effects of acoramidis with and without concomitant tafamidis use.

Ahmad Masri, MD, MS, discusses data detailing the effects of aficamten in oHCM from the FOREST-HCM OLE study at ACC.25.

Jose Lopez, MD, discusses findings and perspective into racial and ethnic differences in DbCM from the ARISE-HF trial.

In this video, the last in a 4-part series, panelists discuss how ongoing research and efforts could shape the future of ATTR-CM management.

In this video, part 3 of a 4-part series, panelists discuss the impact of recent approvals and pipeline developments on the outlook for ATTR-CM management.

In this video, part 2 of a 4-part series, panelists discuss on recent advancements in imaging and biomarker-based diagnostics for ATTR-CM

In this video, part 1 of a 4-part series, panelists discuss recent advancements in ATTR-CM management.